
|Videos|October 24, 2022
Study measures patient rankings of third-line OAB treatments
Author(s)Urology Times staff
“We wanted to help provide an understanding of what factors guide patient choice of third line therapy for overactive bladder,” says Anjali Kapur, MD.
Advertisement
In this video, Anjali Kapur, MD, discusses the background and notable findings of the recent Neurourology and Urodynamics paper, “An analysis of factors that influence patient preference of third-line therapy for overactive bladder.” Kapur is a urology resident at Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD
5





